<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929887</url>
  </required_header>
  <id_info>
    <org_study_id>KORNERSTONE</org_study_id>
    <nct_id>NCT03929887</nct_id>
  </id_info>
  <brief_title>KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis</brief_title>
  <acronym>KORNERSTONE</acronym>
  <official_title>Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KangWon National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glomerulonephritis (GN) generates an enormous individual and social economic burden. However,
      the therapeutic options are largely based on clinical and pathological parameters and the
      individual response to therapy or prognosis is uncertain.

      Recently, along with advances in molecular analysis and computational bioinformatics, genomic
      data from human renal biopsies could provide a strong foundation for the future of precision
      medicine in nephrology.

      In response to a request for applications by the Ministry of Health and Welfare of Korea for
      the creation of Clinical Research Registry, multi-center N network has been established for
      prospective cohort with kidney biopsy samples (KORNERSTONE).

      Through this Network the investigators hope to understand the fundamental biology of
      glomerulonephritis and aim to bank long-term observational data and corresponding biological
      data including genomic data from kidney tissues, and kidney pathologic data which is
      digitalized This database is archived to a web-based platform to access easily and further
      enrich for researchers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental
      glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy
      (IgAN) has quite a common clinical presentation often results in renal insufficiency which
      generates an enormous individual and social economic burden.

      However, the therapeutic options are largely based on clinical and pathological parameters
      and the individual response to therapy or prognosis is uncertain.

      Recently, along with advances in molecular analysis and computational bioinformatics, genomic
      data from human renal biopsies could provide a strong foundation for the future of precision
      medicine in nephrology.

      In response to a request for applications by the Ministry of Health and Welfare of Korea for
      the creation of Clinical Research Registry, a number of universities joined together to
      establish Korean Kidney Biopsy Network (KORNERSTONE).

      Through this Network the investigators hope to understand the fundamental biology of
      glomerulonephritis and aim to bank long-term observational data and corresponding biological
      data including genomic data from kidney tissues, and kidney pathologic data which is
      digitalized This database is archived to a web-based platform to access easily and further
      enrich for researchers.

      ============ &lt;Patient clinical data will be collected as follows&gt;

        1. Blood tests: CBC, Chemistry (Ca, P, Glucose, Total protein, Albumin, Uric acid),
           Electrolyte, Renal function (BUN, Creatinine, eGFR), Liver function (AST, ALT)

        2. Immunologic blood tests: Complement 3, Complement 4, ASO, RF, Cryoglobulin, dsDNA, ANA

        3. Urine tests: Urinalysis, Urine protein, Urine albumin, Urine creatinine

        4. Radiologic tests: Kidney USG, Abdominal-pelvis computed tomography

        5. Pathologic results

        6. Treatment informations: treatment status, drug type, treatment duration

        7. Quality of life questionnaire: Kidney Disease and Quality of Life Short Form survey
           (adults), PedsQL 4.0 Generic Core Scales (pediatrics)

        8. Dietary questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>60 months</time_frame>
    <description>Documentation of death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deterioration of renal outcomes</measure>
    <time_frame>60 months</time_frame>
    <description>Doubling of serum creatinine compared to baseline serum creatinine
30% decline in follow-up estimated GFR (using the MDRD equation and/or the CKD-EPI equation) compared to baseline measurement
End stage renal disease defined as estimated GFR ≤10cc/min, initiation of maintenance dialysis or kidney transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of clinical outcomes</measure>
    <time_frame>60 months</time_frame>
    <description>Remission of glomerulonephritis and proteinuria &lt;0.3g/day (pateint who have proteinuria&lt;0.3g/day at baseline have no improvement in clinical outcomes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malignancies</measure>
    <time_frame>60 months</time_frame>
    <description>Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections, Serious and Systemic</measure>
    <time_frame>60 months</time_frame>
    <description>Documented infection of any vital organ requiring the use of parenteral and/or oral antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>60 months</time_frame>
    <description>Documented diagnosis of acute kidney injury as defined by the RIFLE criteria and/or renal failure requiring renal replacement therapy &lt;3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>60 months</time_frame>
    <description>Documented hospital admission, including observation for ≥24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Department/ Observation Unit Visit</measure>
    <time_frame>60 months</time_frame>
    <description>Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular/Cerebrovascular event</measure>
    <time_frame>60 months</time_frame>
    <description>Myocardial infarction; Congestive heart failure; Primary intractable serious arrhythmia; Peripheral vascular disease; Ischemic cerebrovascular accident; Hemorrhagic cerebrovascular accident; Thromboembolic event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onset Diabetes</measure>
    <time_frame>60 months</time_frame>
    <description>Diagnosis of diabetes as indicated by 1 or more of the following not present at enrollment
Documented diagnosis of diabetes in medical record
Casual (non-fasting) blood glucose &gt; 200 mg/dL c) Fasting blood glucose &gt; 126 mg/dL d) 2 hour glucose &gt; 200 after oral glucose tolerance test e) chronic use (&gt;6 mos) hypoglycemic therapy outside of pregnancy f) Hemogloblin A1C &gt;= 6.5%</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Glomerular Disease</condition>
  <condition>Minimal Change Disease</condition>
  <condition>IgA Nephropathy</condition>
  <condition>Membranous Nephropathy</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Lupus Nephritis</condition>
  <condition>Crescentic Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>KORNERSTONE</arm_group_label>
    <description>Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)
Participants enrolled in KORNERSTONE with a biopsy proven GN.
Eligible participants must be scheduled for a clinically indicated renal biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kidney Biopsy</intervention_name>
    <description>Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.</description>
    <arm_group_label>KORNERSTONE</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, genomic DNA, buffy coat, urine, stool, glomerular cDNA, tubulointerstitial
      cDNA, kidney biopsy slides (digitalized)

      These sample are acquired at kidney biopsy, annually afterwords, and at the time of clinical
      endpoint if possible.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suspected of glomerular diseases who received kidney biopsy in participating
        university medical centres are eligible for inclusion in the KORNERSTONE.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion criteria

               -  Patient suspected of glomerular disease who received kidney biopsy in
                  participating university medical centers

               -  Children (age&lt;18 years) also included

          2. Exclusion criteria - Patients who previously received a kidney transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Ki Kim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Chul Kim, MD,PhD.</last_name>
    <phone>+82-10-8874-7429</phone>
    <email>imyongkim@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eunyoung Kim</last_name>
    <phone>+82-2-6072-5188</phone>
    <email>irish-key@nate.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KangWon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunhwa Lee, MD</last_name>
      <email>bucibuci@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Ji In Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunhwa Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaerim Kim, MD, PhD</last_name>
      <email>yaerim86@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Seungyeup Han, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaerim Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hosptial</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Ho Hwang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jin Ho Hwang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Chul Kim, MD, PhD</last_name>
      <phone>+82-10-8874-7429</phone>
      <email>imyongkim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong Ki Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hajeong Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yon Su Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwon Wook Joo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung Seok Han, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee Gyung Kang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyung Chul Moon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eunjeong Kang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung Hee Yang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nan Kyung Lee, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eunyoung Kim, BN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Tak Park, MD, PhD</last_name>
      <email>JTPARK@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jung Tak Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beom Jin Lim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Nam An, MD, PhD</last_name>
      <email>lovingjn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jung Pyo Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeonghwan Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung Nam An, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeong Hwan Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Dong Ki Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glomerular disease</keyword>
  <keyword>sample repository</keyword>
  <keyword>clinical data</keyword>
  <keyword>digital pathology repository</keyword>
  <keyword>web-based database</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

